Next-Generation Immune-Oncology Drugs Show Early Promise
March 30, 2023
Phipps, Matt
Pricing Restrictions, Economic Concerns Weigh on Biotech Sector
March 30, 2023
Nierengarten, David
Biotechs Hit Bottom and Bounce Back — Twice
August 18, 2022
Nierengarten, David
Slowing of Clinic Trial Data Hampers Early-Stage Biotechs
March 18, 2022
Nierengarten, David
Low Cost of Capital Sets Stage for Uptick in Biotech M&A
March 18, 2021
Nierengarten, David
Seeing a Bifurcation of Therapeutic Focus in the Oncology Space
September 30, 2020
Nierengarten, David
